INGN Quote, Financials, Valuation and Earnings

Glaukos has a net margin of -6.71% compared to Inogen's net margin of -22.15%. Inogen's return on equity of -26.33% beat Glaukos's return on equity of -27.46%.

Inogen has a consensus price target of --, signalling upside risk potential of 4.71%. On the other hand Glaukos has an analysts' consensus of $155.25 which suggests that it could fall by -0.82%. Given that Inogen has higher upside potential than Glaukos, analysts believe Inogen is more attractive than Glaukos.

Inogen has a beta of 1.025, which suggesting that the stock is 2.462% more volatile than S&P 500. In comparison Glaukos has a beta of 1.041, suggesting its more volatile than the S&P 500 by 4.119%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Glaukos pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $88.8M, which are smaller than Glaukos quarterly revenues of $96.7M. Inogen's net income of -$6M is higher than Glaukos's net income of -$21.4M. Notably, Inogen's price-to-earnings ratio is -- while Glaukos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.68x versus 22.18x for Glaukos. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -6.71% compared to Inogen's net margin of 8.28%. Inogen's return on equity of -26.33% beat Globus Medical's return on equity of 2.27%.

Inogen has a consensus price target of --, signalling upside risk potential of 4.71%. On the other hand Globus Medical has an analysts' consensus of $97.85 which suggests that it could grow by 12.38%. Given that Globus Medical has higher upside potential than Inogen, analysts believe Globus Medical is more attractive than Inogen.

Inogen has a beta of 1.025, which suggesting that the stock is 2.462% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $88.8M, which are smaller than Globus Medical quarterly revenues of $625.7M. Inogen's net income of -$6M is lower than Globus Medical's net income of $51.8M. Notably, Inogen's price-to-earnings ratio is -- while Globus Medical's PE ratio is 129.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.68x versus 4.82x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Marinus Pharmaceuticals has a net margin of -6.71% compared to Inogen's net margin of -283.63%. Inogen's return on equity of -26.33% beat Marinus Pharmaceuticals's return on equity of -1150.43%.

Inogen has a consensus price target of --, signalling upside risk potential of 4.71%. On the other hand Marinus Pharmaceuticals has an analysts' consensus of $1.07 which suggests that it could grow by 98.64%. Given that Marinus Pharmaceuticals has higher upside potential than Inogen, analysts believe Marinus Pharmaceuticals is more attractive than Inogen.

Inogen has a beta of 1.025, which suggesting that the stock is 2.462% more volatile than S&P 500. In comparison Marinus Pharmaceuticals has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.471%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marinus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Marinus Pharmaceuticals pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $88.8M, which are larger than Marinus Pharmaceuticals quarterly revenues of $8.5M. Inogen's net income of -$6M is higher than Marinus Pharmaceuticals's net income of -$24.2M. Notably, Inogen's price-to-earnings ratio is -- while Marinus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.68x versus 0.97x for Marinus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals has a net margin of -6.71% compared to Inogen's net margin of --. Inogen's return on equity of -26.33% beat Rocket Pharmaceuticals's return on equity of --.

Inogen has a consensus price target of --, signalling upside risk potential of 4.71%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $43.13 which suggests that it could grow by 287.19%. Given that Rocket Pharmaceuticals has higher upside potential than Inogen, analysts believe Rocket Pharmaceuticals is more attractive than Inogen.

Inogen has a beta of 1.025, which suggesting that the stock is 2.462% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.72700000000001%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $88.8M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Inogen's net income of -$6M is higher than Rocket Pharmaceuticals's net income of -$66.7M. Notably, Inogen's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.68x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.